Skip to main content
S 4760 116th Congress Senate Health Administrative law and regulatory procedures Advisory bodies Appropriations Department of Health and Human Services Drug therapy Executive agency funding and structure Government information and archives Government studies and investigations Health information and medical records Infectious and parasitic diseases Medical research Prescription drugs Public contracts and procurement Research and development

The PASTEUR Act

Introduced: September 30, 2020 Introduced by: Bennet, Michael F. Democratic · Colorado See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 30, 2020
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sep 30, 2020
Introduced in Senate
 Plain-English summary Congressional Research Service

The Pioneering Antimicrobial Subscriptions To End Up surging Resistance Act of 2020 or The PASTEUR Act

This bill authorizes the Department of Health and Human Services (HHS) to enter into subscription contracts for critical-need antimicrobial drugs, provides $11 billion in appropriations for activities under the bill, and contains other related provisions.

A manufacturer of a Food and Drug Administration-approved antimicrobial drug may apply to HHS to have the drug designated as a critical-need antimicrobial, and HHS may enter into a subscription contract for such a critical-need antimicrobial. The bill imposes certain requirements related to such contracts, including a mechanism to lower payments under the contract in certain instances to limit the manufacturer's revenue from the drug.

Furthermore, HHS and the Centers for Disease Control and Prevention shall award grants to support efforts to encourage the appropriate use of antimicrobial drugs and efforts to combat antimicrobial resistance.

HHS shall also establish a Committee on Critical Need Antimicrobials. The committee shall develop a list of prioritized infections for which new antimicrobial drug development is needed, among other duties.

Within six years of the bill's enactment, the Government Accountability Office shall report to Congress a study on the bill's effectiveness in developing priority antimicrobial drugs.

What's happening now September 30, 2020

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Committees of jurisdiction 1
 Cosponsors 1
All 1 Republican 1